Patent ID: 9523130
Filing Date: 2016-12-20
CPC Classification: A61K,A61P,C07K,C12N,C12Q,C12Y,G01N

Claim Text:
1. A method for treating a human subject having a non-small cell lung carcinoma (NSCLC) that expresses a human Echinoderm Microtubule-Associated Protein-Like 4 (EML4)-Anaplastic Lymphoma Kinase (ALK) fusion polypeptide, comprising administering to the human subject a small molecule that a) binds to the ATP-binding cleft and b) directly inhibits the kinase activity of the EML4-ALK fusion polypeptide, in an amount effective to treat the NSCLC, wherein i) the EML4-ALK fusion polypeptide comprises an amino acid sequence that is at least 95% identical to an amino acid sequence comprising EML4 amino acid residues 1-222 of SEQ ID NO: 3 and ALK amino acid residues 1116-1383 of SEQ ID NO: 5 and ii) the EML4 amino acid residues are amino-terminal to the ALK amino acid residues.